Literature DB >> 15931323

Contrast nephropathy.

Shereif H Rezkalla1.   

Abstract

Contrast nephropathy will increase mortality up to 30% following angiographic procedures. Before performing such procedures a careful reassessment of the risk/benefit ratio should be performed. Mannitol and diuretics play no role in prevention. Hydration and correction of abnormal electrolyte levels should be done in all patients. Pre-treatment with acetylcysteine and theophylline is a well-accepted strategy and should always be utilized. If creatinine levels are above 2.5 to 3 mg/dl, fenoldopam may provide additional protection, particularly in diabetic patients. However, the role of fenoldopam is controversial. Prophylactic hemodialysis may prove to be an additional tool in the fight against this disease in selected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15931323      PMCID: PMC1069059          DOI: 10.3121/cmr.1.4.301

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  33 in total

1.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

Authors:  Larry J Diaz-Sandoval; Bernard D Kosowsky; Douglas W Losordo
Journal:  Am J Cardiol       Date:  2002-02-01       Impact factor: 2.778

2.  Usefulness of rotational spin for coronary angiography in patients with advanced renal insufficiency.

Authors:  Eberhard Kuon; Pierre N Niederst; Johannes B Dahm
Journal:  Am J Cardiol       Date:  2002-08-15       Impact factor: 2.778

3.  Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study.

Authors:  Wolfgang Huber; Kathrin Ilgmann; Michael Page; Michael Hennig; Ursula Schweigart; Barbara Jeschke; Leopoldo Lutilsky; Wolfgang Weiss; Hermann Salmhofer; Meinhard Classen
Journal:  Radiology       Date:  2002-06       Impact factor: 11.105

4.  Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography.

Authors:  P J Conlon; M A Little; K Pieper; D B Mark
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

5.  Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.

Authors:  J A Tumlin; A Wang; P T Murray; V S Mathur
Journal:  Am Heart J       Date:  2002-05       Impact factor: 4.749

6.  The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with chronic renal failure.

Authors:  L Gruberg; R Waksman; A E Ajani; H S Kim; R L White; E Pinnow; R Deible; L F Satler; A D Pichard; K K Kent; J Lindsay
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

7.  Acetylcysteine and contrast agent-associated nephrotoxicity.

Authors:  Carlo Briguori; Fiore Manganelli; Pierfranco Scarpato; Pietro Paolo Elia; Bruno Golia; Guido Riviezzo; Stefano Lepore; Mariateresa Librera; Bruno Villari; Antonio Colombo; Bruno Ricciardelli
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

8.  Mild renal insufficiency is associated with angiographic coronary artery disease in women.

Authors:  Steven E Reis; Marian B Olson; Linda Fried; Virginia Reeser; Sunil Mankad; Carl J Pepine; Richard Kerensky; C Noel Bairey Merz; Barry L Sharaf; George Sopko; William J Rogers; Richard Holubkov
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

Review 9.  Acetylcysteine and contrast media nephropathy.

Authors:  Martin Tepel; Walter Zidek
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-09       Impact factor: 2.894

10.  Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review.

Authors:  Wolfgang Huber; Barbara Jeschke; Bernhard Kreymann; Michael Hennig; Michael Page; Hermann Salmhofer; Florian Eckel; Ulrike Schmidt; Andreas Umgelter; Ursula Schweigart; Meinhard Classen
Journal:  Invest Radiol       Date:  2002-09       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.